Pro-Dex (NASDAQ:PDEX) Price Target Raised to $30.00

Pro-Dex (NASDAQ:PDEX) had its price objective upped by Ascendiant Capital Markets from $28.00 to $30.00 in a research report released on Monday, Marketbeat reports. Ascendiant Capital Markets currently has a buy rating on the medical instruments supplier’s stock.

Separately, StockNews.com raised Pro-Dex from a buy rating to a strong-buy rating in a research report on Saturday, September 7th.

Pro-Dex Stock Up 1.5 %

Shares of NASDAQ:PDEX opened at $26.10 on Monday. The company has a 50 day moving average price of $20.43 and a two-hundred day moving average price of $19.11. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.66 and a current ratio of 2.84. The company has a market capitalization of $89.24 million, a PE ratio of 45.00 and a beta of 0.38. Pro-Dex has a 52 week low of $14.51 and a 52 week high of $27.62.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings data on Thursday, September 5th. The medical instruments supplier reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.11. The business had revenue of $15.03 million during the quarter. Pro-Dex had a net margin of 3.95% and a return on equity of 6.82%.

Insider Transactions at Pro-Dex

In related news, Director Angelita Rebamontan Domingo sold 2,585 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $18.30, for a total value of $47,305.50. Following the sale, the director now directly owns 8,191 shares of the company’s stock, valued at approximately $149,895.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 42.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PDEX. Dimensional Fund Advisors LP boosted its position in Pro-Dex by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after acquiring an additional 3,067 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares in the last quarter. Finally, Perritt Capital Management Inc. lifted its position in shares of Pro-Dex by 43.3% in the first quarter. Perritt Capital Management Inc. now owns 6,000 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 1,813 shares in the last quarter. 15.28% of the stock is currently owned by institutional investors.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.